This forms a key part of ADC Bio’s construction of a new bioconjugation facility at its site in Deeside, North Wales, UK for the commercial production of antibody drug conjugates in response to global customer demand.
Antibody drug conjugates are a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards.
WHP, the multi-disciplinary engineering company, was awarded the £5m contract in December 2017, and the new facility - which includes support areas for washing, depyrogenation, thawing and buffer preparation - sees drug manufacturing in a stringently controlled environment, operated under cGMP regulations. This eliminates any risks during antibody modification and conjugation that could support the development of environmentally-borne microbial contaminants.
WHP’s scope of work covered the design and build, including test and validation of a state-of-the-art containment manufacturing cleanroom within an existing 6,500m2 high tech facility, along with new quality control and process development laboratories.
Charlie Johnson, CEO at ADC Bio, said: “We are building a best in class facility to the highest possible global standards. We awarded the contract to WHP on the back of its relevant industry experience and reputation for delivering cost-effective, single source cleanroom design and build packages.
“It’s a facility we are extremely proud of that will help our customers develop vital new medicines for patients globally.”
WHP’s project manager, Chris Douglas, said: “The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure and highly efficient manufacturing capabilities.“This latest project reflects growing success in delivering high quality cleanroom technologies across the pharmaceutical sector, providing customers with expertise, knowledge and one-stop-shop solutions.”